TBA

TBA

Mr. Lake has worked in vaccine manufacturing and commercialization for 30 years developing diverse experience at global leaders Merck and GlaxoSmithKline. Mr. Lake's background includes live virus and recombinant vaccine bulk production, sterile filling, and quality control, before moving into product management and business development roles. He served as the manufacturing Alliance Manager between Merck and Sanofi Pasteur during the startup of their European Joint Venture and worked for several years as a senior level commercialization consultant in the vaccine industry.

TBD

Stephen Harhen is the Chief Technology Officer at Rx Bandz, where he leads the design and development of MiniJect® and oversees drug development to create the next-generation autoinjector platform. With over 15 years of experience spanning combination products, drug-device integration, and medical device R&D, Stephen brings a uniquely cross-functional perspective to solving complex technical challenges at the interface of engineering and therapeutics.

Mark R. Prausnitz is Regents’ Professor, Regents' Entrepreneur and J. Erskine Love, Jr. Chair in Chemical & Biomolecular Engineering at the Georgia Institute of Technology in Atlanta, GA. He carries out research on biophysical methods of drug delivery using microneedles, lasers, ionic liquids and other microdevices for transdermal, ocular and intracellular delivery of drugs and vaccines. He has published more than 350 journal articles, invented more than 75 US patents, was elected to the National Academy of Engineering, National Academy of Medicine, and National Academy of Inventors, and has co-founded ten start-up companies including Micron Biomedical, Clearside Biomedical, and Alys Pharmaceuticals.

Rebecca Sayers is the head of IQVIA’s Site Enablement Solutions team, a service offering within IQVIA’s Global Patient & Site Solutions aimed at overcoming site-level resourcing barriers by providing research-experienced research staff to support clinical trial protocols. Dr Sayers brings 10+ years in the clinical research industry to the role, with her prior experience focused on site engagement and support to impact patient recruitment. With a keen view to the challenges facing global clinical trial sites, especially following the COVID-19 pandemic, she combines her awareness of trial site challenges with her ability to draw on multidisciplinary CRO solutions to optimize site performance.

Ralph Passarella is a Co-founder of Care Access, a global clinical research company focused on making clinical trials more accessible for communities; and, faster and more predictable for life science companies. Ralph is also the Co-founder and CEO of Reify Health and Co-founder of Signal Vine, an education technology company that was spun out of Reify Health and is focused on helping students navigate the administrative parts of higher education.

Mike Franklin is Vice President of Community Based Research at Eli Lilly and Company. In his role, he is responsible for the delivery of a global strategy to bring research, awareness, and accessibility of clinical trials into the communities that these medicines will ultimately serve. Mike has over 30 years of drug development experience across the pharmaceutical & research industry.